1. MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A
    WENWEI YE et al, 2014, Oncology Reports CrossRef
  2. Metformin Enhances Nomegestrol Acetate Suppressing Growth of Endometrial Cancer Cells and May Correlate to Downregulating mTOR Activity In Vitro and In Vivo
    Can Cao et al, 2019, International Journal of Molecular Sciences CrossRef
  3. Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells
    Tomohiko Fukuda et al, 2016, Oncology Letters CrossRef
  4. Role of Tricellular Tight Junction Protein Lipolysis-Stimulated Lipoprotein Receptor (LSR) in Cancer Cells
    Takayuki Kohno et al, 2019, International Journal of Molecular Sciences CrossRef
  5. Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
    Raya Faigenbaum et al, 2013, Oncotarget CrossRef

  6. MiR-486-5p Act as a Biomarker in Endometrial Carcinoma: Promotes Cell Proliferation, Migration, Invasion by Targeting MARK1


    Xiaojiao Zheng et al, 2020, OncoTargets and Therapy CrossRef
  7. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
    Angiolo Gadducci et al, 2016, Critical Reviews in Oncology/Hematology CrossRef
  8. Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment
    Amanda de Barros Machado et al, 2016, Oncology Letters CrossRef
  9. TRIM22 inhibits endometrial cancer progression through the NOD2/NF‑κB signaling pathway and confers a favorable prognosis
    Liping Zhang et al, 2020, International Journal of Oncology CrossRef
  10. Are growth factor receptors modulated by metformin in human endometrial stromal cells after stimulation with androgen and insulin?
    Gustavo Dias Ferreira et al, 2014, Archives of Gynecology and Obstetrics CrossRef
  11. MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7
    QUAN LI et al, 2015, Oncology Reports CrossRef
  12. Depleted-MLH1 Expression Predicts Prognosis and Immunotherapeutic Efficacy in Uterine Corpus Endometrial Cancer: An In Silico Approach
    Tesfaye Wolde et al, 2024, BioMedInformatics CrossRef
  13. Circ_0067835 sponges miR‐324‐5p to induce HMGA1 expression in endometrial carcinoma cells
    Yun Liu et al, 2020, Journal of Cellular and Molecular Medicine CrossRef
  14. Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
    Mu Lv et al, 2022, Cancers CrossRef
  15. Sudden death of a middle aged woman with a series of undiagnosed gynaecologic diseases
    Wakako Hikiji et al, 2014, Forensic Science International CrossRef
  16. High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer
    John J. Wallbillich et al, 2017, PLOS ONE CrossRef
  17. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6
    Hirofumi Ando et al, 2017, Hormones and Cancer CrossRef
  18. Recent advances in research on epigenetic alterations and clinical significance of para-aortic lymphadenectomy in endometrial cancer: an introduction
    Noriaki Sakuragi, 2013, International Journal of Clinical Oncology CrossRef
  19. The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cells
    Hiroshi Shimada et al, 2016, Oncotarget CrossRef
  20. FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt
    Jing Dong et al, 2017, Oncotarget CrossRef
  21. mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View
    Katsutoshi Oda et al, 2015, Current Obstetrics and Gynecology Reports CrossRef
  22. Study on the Anti‐Endometrial Cancer Activity of a Series of 4,6‐Diaryl‐2‐pyrimidinamine Derivatives against Endometrial Carcinoma Ishikawa Cell and Their Molecular Design
    Qi Yang et al, 2018, ChemistrySelect CrossRef